Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $18.4 million.

  • Tango Therapeutics' Total Current Liabilities fell 5092.46% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year decrease of 5092.46%. This contributed to the annual value of $38.2 million for FY2024, which is 1690.97% down from last year.
  • Latest data reveals that Tango Therapeutics reported Total Current Liabilities of $18.4 million as of Q3 2025, which was down 5092.46% from $40.0 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Total Current Liabilities ranged from a high of $55.5 million in Q4 2022 and a low of $301964.0 during Q1 2021
  • Over the past 5 years, Tango Therapeutics' median Total Current Liabilities value was $42.0 million (recorded in 2021), while the average stood at $38.3 million.
  • In the last 5 years, Tango Therapeutics' Total Current Liabilities surged by 3639369.84% in 2021 and then tumbled by 5092.46% in 2025.
  • Tango Therapeutics' Total Current Liabilities (Quarter) stood at $40.7 million in 2021, then skyrocketed by 36.51% to $55.5 million in 2022, then fell by 17.3% to $45.9 million in 2023, then dropped by 16.91% to $38.2 million in 2024, then plummeted by 51.68% to $18.4 million in 2025.
  • Its Total Current Liabilities was $18.4 million in Q3 2025, compared to $40.0 million in Q2 2025 and $35.9 million in Q1 2025.